MRNA · News · 20260817N
Regulatory Approval Milestones
Moderna, Inc. · 2026-08-17 · Importance 71 · Surprise 60 · In source text
The FDA approved Moderna’s mFlusiva, the first mRNA flu vaccine in the United States for adults aged 50 and older. The approval opens a new seasonal influenza market and expands Moderna’s commercial portfolio beyond COVID-19 vaccines. Analysts expect limited near-term revenue because the vaccine missed annual contracting cycles, but project potential annual sales of approximately $1.1 billion by 2027. Commercial adoption may be challenged by skepticism toward mRNA technology, annual strain-selection timing, and the need for broader international regulatory acceptance.
Key facts
- The FDA approved mFlusiva, the first mRNA flu vaccine in the U.S. for adults 50 and older. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | The FDA approved mFlusiva, the first mRNA flu vaccine in the U.S. for adults 50 and older. |